

Beslutningsforum sier ja til LIBTAYO® (cemiplimab)

og innfører dermed immunterapi i behandlingen av plateepitelkarsinom fra 15. desember 2020.

Indikasjon:

Produktet innføres som monoterapi til behandling av voksne med metastatisk (mCSCC) eller lokalavansert (laCSCC) kutant plateepitelkarsinom (CSCC), som ikke er egnet for kurativ kirurgi eller kurativ strålebehandling.

“At immunbehandling nå kan tilbys pasienter med avansert plateepitelkarsinom i hud, er et stort og viktig fremskritt. Systemisk behandling av hudkreft-pasienter har inntil nå vært begrenset til få og lite effektive medikamenter. En studie har vist at cemiplimab gav behandlingsrespons hos 44 % av pasientene. Dette er et imponerende resultat.”, sier Åse Bratland, MD, ph.d., overlege og leder for seksjon hode-halskreft, Oslo universitetssykehus Radiumhospitalet.

Dette er den eneste godkjente immunterapibehandlingen i Norge for voksne pasienter med metastatisk eller lokalavansert plateepitelkreft, som ikke er kandidater for kurativ kirurgi eller kurativ strålebehandling. Preparatet fikk markedsføringstillatelse i Norge 28. juni 2019 og ble besluttet innført som behandling i Beslutningsforum 23. november 2020.

Avansert plateepitelkreft (CSCC) er en av de vanligste formene for hudkreft, og er spesielt vanskelig å behandle i senere stadier.^{i-v}

“Dette er en gledelig nyhet for norske pasienter som nå får tilgang til en helt ny kreftbehandling på dette området”, sier Britt Moe Flatla, daglig leder Sanofi Genzyme Norge.

Om produktet

Dette er et humanisert monoklonalt antistoff som binder seg til programmert celledød-1 (PD-1) reseptoren, og blokkerer dens interaksjon med ligandene PD-L1 og PD-L2. Preparatet er den første og eneste godkjente behandlingen for avansert plateepitelkreft (CSCC) i EU.

Avansert plateepitelkreft inkluderer både pasienter med lokal-avansert sykdom (hvor kreften ikke kan kureres med kirurgi og/eller strålebehandling) og pasienter med metastatisk sykdom (hvor kreften har spredd seg til andre deler av kroppen). Basert på historiske data, har pasienter med påvist avansert plateepitelkreft forventet levetid på omtrent ett år.^{vii-x}

Europakommisjonens godkjenning er basert på data fra det pivotale, åpne, multisenter, ikke-randomiserte, fase 2-studie EMPOWER-CSCC-1 (Studie 1540).

Studien er støttet av to utvidede avanserte plateepitelkreft kohorter fra den ikke-randomiserte, åpne, multisenter, fase 1-Studien 1423.

Studiene representerer en av de største kliniske datasettene som eksisterer i dag for å kunne evaluere systematisk terapi blant pasienter med avansert plateepitelkreft.

Legemiddelet er utviklet av Sanofi og Regeneron under en internasjonal samarbeidsavtale

Les mer her:

About Libtayo

In addition to the EU, the drug is also approved in the U.S., Canada and Brazil for adult patients with metastatic CSCC or locally advanced CSCC who are not candidates for curative surgery or curative radiation. In the U.S., the generic name for the drug is cemiplimab-rwlc, with rwlc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration.

Beyond the ongoing EMPOWER-CSCC-1 trial, the drug is also being investigated in adjuvant and neoadjuvant trials in CSCC and in potential registrational trials in non-small cell lung cancer, basal cell carcinoma and cervical cancer. Additional studies include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma and non-Hodgkin's lymphoma. These trials are designed to investigate the drug as monotherapy; in combination with conventional treatments like chemotherapy; or in combination with other investigational agents, including vaccines, oncolytic viruses and bispecific antibodies, among others. These potential uses are investigational, and their safety and efficacy have not been evaluated by any regulatory authority.

About Regeneron Pharmaceuticals, Inc.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases. Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Mediekontakt

Britt Moe Flatla
Tel.: (+47) 97 76 52 07
britt.moe@sanofi.com

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product.

Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks

and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the absence of guarantee that the product will be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic conditions, as well as those risks discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2018. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Libtayo® (cemiplimab) Injection for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation and other potential indications; whether any product labelling or other changes may be required by the European Medicines Agency in the future in connection with the conditional approval for Libtayo discussed in this press release; the likelihood and timing of achieving any of Regeneron's anticipated clinical development milestones; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates (such as Libtayo) in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products, including without limitation any possible regulatory approval of Libtayo (as a monotherapy or in combination with conventional treatments or other investigational agents, as applicable) for the treatment of non-small cell lung cancer, basal cell carcinoma, cervical cancer, squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate cancer, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and other potential indications; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as Libtayo), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; the availability and extent of reimbursement of the Company's

products (such as Libtayo) from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation and other related proceedings relating to EYLEA® (afibercept) Injection, Dupixent® (dupilumab) Injection, and Praluent® (alirocumab) Injection, the ultimate outcome of any such proceedings, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the fiscal year ended December 31, 2018 and its Form 10-Q for the quarterly period ended March 31, 2019. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (<http://newsroom.regeneron.com>) and its Twitter feed (<http://twitter.com/regeneron>).

-
- ⁱ Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease [published online June 29, 2016]. *Am J Clin Dermatol*. 2016;17(5):491-508. doi:10.1007/s40257-016-0207-3
- ⁱⁱ Brunner M, Veness MJ, Ch'ng S, Elliott M, Clark JR. Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV. *Head Neck*. 2013;35(1):72-75. ⁱⁱⁱ Califano JA, Lydiatt WM, Nehal KS, et al. Cutaneous squamous cell carcinoma of the head and neck. In: Amin MB, Edge SB, Greene FL, et al, eds. *AJCC Cancer Staging Manual*. 8th ed. Springer; 2017:171181. ^{iv} Skin cancer treatment (PDQ®). National Cancer Institute website. <https://www.cancer.gov/types/skin/hp/skin-treatment-pdq>. Updated February 1, 2018. Accessed February 13, 2018. ^v Jennings L, Schmults CD. Management of high-risk cutaneous squamous cell carcinoma. *J Clin Aesthet Dermatol*. 2010;3(4):39-48.
- ^{vi} Stratigos, Alexander et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. *European Journal of Cancer*, Vol 51(14);14, 1989-2007 ^{vii} Jarkowski, A. (2014). Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC). *American Journal of Clinical Oncology*, 00(00), 1-4. ^{viii} Foote, M.C. (2014). Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. *Annals of Oncology*, 25, 2047–2052.
- ^{ix} Maubec, E. (2001). Phase II Study of Cetuximab As First-Line Single-Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin. *J Clin Oncol*, 29 (25), 3419-3426.
- ^x Cowey CL, et al. Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma (CSCC) in a US community oncology setting. *J Clin Oncol* 37, 2019 (suppl; abstr e21033).